Projects per year
Personal profile
Biography
Chrishan is a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory, Department of Pharmacology at Monash. Having been trained as a matrix biologist, his research is focused on identifying novel therapeutic targets and more direct and potent treatment strategies for fibrosis (organ scarring) prevention; particularly associated with cardiovascular, renal and allergic airways diseases. Chrishan's main interest has been to establish the anti-fibrotic and therapeutic potential of the naturally occurring hormone, relaxin. He additionally investigates other novel anti-fibrotics and repair factors, as well as combination therapies that may aid in tissue repair and regeneration, in collaboration with others.
Research area keywords
- Fibrosis
- Cardiovascular disease
- Kidney Disease
- Lung Disease
- Stem Cell Biology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Novel angiotensin therapies to treat liver fibrosis
Widdop, R. (Primary Chief Investigator (PCI)), Del Borgo, M. (Chief Investigator (CI)), Majumdar, A. (Chief Investigator (CI)), Wang, Y. (Chief Investigator (CI)), Simon, B. (Chief Investigator (CI)), Asadi, K. (Associate Investigator (AI)), Robert, R. (Associate Investigator (AI)), Samuel, C. (Associate Investigator (AI)), Madder, A. (Associate Investigator (AI)), Herath, C. (Chief Investigator (CI)) & Gaspari, T. (Associate Investigator (AI))
1/01/26 → 31/12/29
Project: Research
-
Engineering bone marrow-derived stromal cells to express anti-fibrotic cargo as a treatment for chronic kidney disease
Samuel, C. (Primary Chief Investigator (PCI)), Ricardo, S. (Chief Investigator (CI)), Kerr, P. (Chief Investigator (CI)), Li, T. (Chief Investigator (CI)), Jenkin, G. (Chief Investigator (CI)), Hudson, P. (Chief Investigator (CI)), Polo, J. (Associate Investigator (AI)), Widdop, R. (Associate Investigator (AI)), Nikolic-Paterson, D. (Associate Investigator (AI)) & Teo, L. (Associate Investigator (AI))
1/01/23 → 31/12/26
Project: Research
-
Assessing the toxicity of repeated orally-administered glycine-coated biodegradable superparamagnetic iron oxide nanoparticles (SPIONs) as drug delivery vehicles
Samuel, C. (Primary Chief Investigator (PCI)) & Chakraborty, A. (Chief Investigator (CI))
2/09/24 → 28/02/25
Project: Research
-
Ferring Innovation Grant for Racial Equality in Reproductive Medicine and Maternal Health: Inflammasomes, novel regulators of placental inflammation and placental ageing in early-onset preeclampsia: potential biomarkers to identify ethnic disparity in preeclampsia
Murthi, P. (Primary Chief Investigator (PCI)), Kumar, B. (Chief Investigator (CI)), Samuel, C. (Chief Investigator (CI)), Chakraborty, A. (Chief Investigator (CI)), Brennecke, S. P. (Chief Investigator (CI)) & Karanam, V. (Chief Investigator (CI))
1/12/21 → 1/11/22
Project: Research
-
MediBeacon Transdermal Mini Fluorophore Monitors
Colafella, K. (Primary Chief Investigator (PCI)), Denton, K. (Chief Investigator (CI)), Bubb, K. (Chief Investigator (CI)), Cowley, M. (Chief Investigator (CI)), Widdop, R. (Chief Investigator (CI)), Lyras, D. (Chief Investigator (CI)), Samuel, C. (Chief Investigator (CI)), Bertram, J. (Chief Investigator (CI)) & Parkington, H. (Chief Investigator (CI))
1/10/21 → 31/12/22
Project: Research
-
Corrigendum to “Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice,”(Biomedicine & Pharmacotherapy, (2023), 158, C, (114069), (S0753332222014585), 10.1016/j.biopha.2022.114069)
Li, Y., Zheng, G., Salimova, E., Broughton, B. R. S., Ricardo, S. D., de Veer, M. & Samuel, C. S., Mar 2026, In: Biomedicine and Pharmacotherapy. 196, 1 p., 119143.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
Exploring the anti-inflammatory and anti-fibrotic activity of NFκB decoy oligodeoxynucleotide-loaded spermine-functionalized acetalated nanoparticles
De Rubis, G., Chakraborty, A., Paudel, K. R., Wang, C., Kannaujiya, V., Wich, P., Hansbro, P. M., Samuel, C. S., Oliver, B. & Dua, K., 1 Jun 2024, In: Chemico-Biological Interactions. 396, 6 p., 111059.Research output: Contribution to journal › Article › Research › peer-review
Open Access5 Link opens in a new tab Citations (Scopus) -
Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis
Samuel, C. S., Li, Y., Wang, Y. & Widdop, R. E., Jul 2024, In: British Journal of Pharmacology. 181, 14, p. 2302-2318 17 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access9 Link opens in a new tab Citations (Scopus) -
Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness
Chakraborty, A., Wang, C., Hodgson-Garms, M., Broughton, B. R. S., Frith, J. E., Kelly, K. & Samuel, C. S., Sept 2024, In: Biomedicine & Pharmacotherapy. 178, 16 p., 117259.Research output: Contribution to journal › Article › Research › peer-review
Open Access16 Link opens in a new tab Citations (Scopus) -
Sex- and time-dependent role of insulin regulated aminopeptidase in lipopolysaccharide-induced inflammation
Vear, A., Chakraborty, A., Fahimi, F., Ferens, D., Widdop, R., Samuel, C. S., Gaspari, T., van Endert, P. M. & Chai, S. Y., 2024, In: Frontiers in Immunology. 15, 18 p., 1466692.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Link opens in a new tab Citation (Scopus)